Under the agreement, Lonza is responsible to produce materials for Phase 2 trial at its mammalian development and manufacturing plant.
IMMUNE claims its human immunoglobulin monoclonal antibody Bertilimumab is useful for eosinophilic inflammatory bowel diseases (IBD) -Crohn’s disease and ulcerative colitis- and eosinophilic gastro-intestinal diseases (EGID).
IMMUNE CEO Daniel Teper said the company strengthened its internal bio-manufacturing expertise by appointing David Naveh, former chief technical officer of Bayer Biologics Worldwide, to its board of directors.